Dr Giannis Mountzios speaks to ecancer about the DeLLphi-304 study.

This analysis highlights the intracranial efficacy of tarlatamab, a bispecific T-cell engager immunotherapy, in patients with small cell lung cancer (SCLC) and brain metastases.

Tarlatamab demonstrated significantly improved central nervous system progression-free survival and overall survival compared to chemotherapy, along with higher rates of tumour shrinkage and complete responses in the brain. Responses were also more durable, reinforcing its activity in this difficult-to-treat population.

The safety profile was manageable and consistent with previous findings, including expected immune-related events such as cytokine release syndrome and neurologic effects.

These results support tarlatamab as an effective second-line treatment option for SCLC, including for patients with brain metastases, where therapeutic options remain limited.